These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3166103)

  • 21. Comparison of portal and peripheral blood levels of carcinoembryonic antigen, CA 19-9, and CA 125 tumor-associated antigens in patients with colorectal and pancreatic cancer.
    Talbot RW; Nagorney DM; Pemberton JH; Wieand HS; Ritts RE
    Cancer Res; 1989 Feb; 49(3):542-3. PubMed ID: 2910474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
    Grotowski M; Maruszyński M; Piechota W
    Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of the tumor markers CEA and CA 19-9 in colorectal diagnosis].
    Heptner G; Domschke S; Krapf F; Schneider MU; Iro H; Domschke W
    Dtsch Med Wochenschr; 1984 Aug; 109(35):1309-12. PubMed ID: 6590287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
    Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
    Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
    Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
    Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer.
    Gebauer G; Müller-Ruchholtz W
    Cancer Detect Prev; 2001; 25(4):344-51. PubMed ID: 11531011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Using CEA for diagnostic, therapeutic and prognostic evaluation in colorectal cancers].
    Terabe K; Ichihashi H; Kamei H; Kondo T
    Gan To Kagaku Ryoho; 1984 Jan; 11(1):111-6. PubMed ID: 6696454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients.
    Ohuchi N; Takahashi K; Matoba N; Sato T; Taira Y; Sakai N; Masuda M; Mori S
    Jpn J Clin Oncol; 1989 Sep; 19(3):242-8. PubMed ID: 2810823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sensitivity and specificity of CEA, Ca 15-3 and MCA levels in visceral breast carcinoma metastasis].
    Delbrück H; Hagen-Aukamp C; Braun G
    Strahlenther Onkol; 1990 Jul; 166(7):457-9. PubMed ID: 2200152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical evaluation of CEA in colorectal carcinoma].
    Shimoyama T; Fukuda Y; Itoh S; Shimizu T; Kawaguchi A; Mori M; Ishii T; Miura T; Tomita M
    Gan No Rinsho; 1985 May; 31(6 Suppl):648-54. PubMed ID: 3897618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
    Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of combined CA-19-9 and CEA assay in monitoring recurrences and metastases of colorectal cancer].
    Yu BM
    Zhonghua Wai Ke Za Zhi; 1992 Dec; 30(12):707-9, 777. PubMed ID: 1339738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CEA and NCA levels in peripheral and tumour venous blood of patients with gastric and colonic carcinomas estimated by RIA and EIA methods.
    Harłozińska A; Rachel F; Gawlikowski W; Richter R; Kołodziej J
    Eur J Surg Oncol; 1991 Feb; 17(1):59-64. PubMed ID: 1995360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The significance of CA19-9 tumor antigen in the serum of patients with carcinomas.
    Wang FM; Tsai LC; Chang ZN; Han SH; Tsao D
    Proc Natl Sci Counc Repub China B; 1985 Apr; 9(2):119-25. PubMed ID: 3863154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients.
    Nakayama T; Watanabe M; Teramoto T; Kitajima M
    Anticancer Res; 1997; 17(2B):1379-82. PubMed ID: 9137502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance.
    Gebauer G; Müller-Ruchholtz W
    Anticancer Res; 1997; 17(4A):2731-4. PubMed ID: 9252706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis.
    Shimizu M; Saitoh Y; Ohyanagi H; Itoh H
    Arch Pathol Lab Med; 1990 Feb; 114(2):195-200. PubMed ID: 1689141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carcinoembryonic antigen in patients with colorectal cancer: correlation between stage of disease and antigen level.
    Bartal AH; Ayalon D; Cordova T; Avidan S; Robinson E
    Isr J Med Sci; 1983 Sep; 19(9):801-5. PubMed ID: 6643017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Studies on the clinical evaluation of tissue polypeptide antigen (TPA) levels in the peripheral and draining venous blood of gastric cancer patients].
    Funasaka M; Tabuchi Y; Saitoh Y
    Nihon Geka Gakkai Zasshi; 1991 May; 92(5):506-12. PubMed ID: 1875891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.